Filing Flows › Arcadia Biosciences (RKDA) › Q2 2026
Arcadia Biosciences (RKDA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Arcadia Biosciences (RKDA) reported revenue of $1.4M for the second quarter 2026 (Q2 2026), -0.8% from a year earlier and +31% from the quarter before. Operating margin was -34.4%, net loss $6.3M (434.2% of revenue).
Arcadia Biosciences, Q2 2026: revenue $1.4M (-0.8% year over year), operating margin -34.4%, net loss $6.3M, operating cash flow −$319K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | +31% | -0.8% |
| Operating profit | −$496K | — | — |
| Net earnings | −$6.3M | — | — |
| Operating cash flow | −$319K | — | — |
What changed
Revenue was $1.4M in Q2 2026, down 1% year over year and up 31% from the previous quarter.
Operating costs exceeded revenue by $496K, an operating margin of -34.4%. Total costs fell 1% while revenue fell 1%. The quarter ended with a net loss of $6.3M, wider than the previous quarter's $4.4M loss. Net interest and other expense of $5.8M was the main reason.
Operating cash flow was −$319K. Non-cash charges added back $14K of share-based compensation. Working capital and other items added $5.9M.
Questions
What was Arcadia Biosciences' revenue in the second quarter 2026?
Arcadia Biosciences (RKDA) reported revenue of $1.4M for the second quarter 2026 (Q2 2026), -0.8% from a year earlier and +31% from the quarter before.
Was Arcadia Biosciences profitable in the second quarter 2026?
Operating loss was $496K (-34.4% of revenue) and net loss $6.3M.